APO Research
Talk to an analyst

APO RESEARCH · REPORT

Postmenopausal Vaginal Atrophy (PVA) Therapeutics

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Industry Growth and Trends Forecast to 2032

20 December 202587 pages

Choose your research edition.

Industry ResearchPostmenopausal Vaginal Atrophy (PVA) Therapeutics Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Postmenopausal Vaginal Atrophy (PVA) Therapeutics Industry Growth and Trends Forecast to 203287 pages · $3,450 USDMarket StructureGlobal Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032186 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

According to APO Research, the global Postmenopausal Vaginal Atrophy (PVA) Therapeutics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Postmenopausal Vaginal Atrophy (PVA) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Postmenopausal Vaginal Atrophy (PVA) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Postmenopausal Vaginal Atrophy (PVA) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global companies in the Postmenopausal Vaginal Atrophy (PVA) Therapeutics market include Teva Pharmaceuticals, Pfizer, Shionogi & Co, Novo Nordisk, Endoceutics and Accord Healthcare, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Postmenopausal Vaginal Atrophy (PVA) Therapeutics market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Postmenopausal Vaginal Atrophy (PVA) Therapeutics market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Postmenopausal Vaginal Atrophy (PVA) Therapeutics market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Postmenopausal Vaginal Atrophy (PVA) Therapeutics.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading companies in the global Postmenopausal Vaginal Atrophy (PVA) Therapeutics market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market by Company

Teva Pharmaceuticals

Pfizer

Shionogi & Co

Novo Nordisk

Endoceutics

Accord Healthcare

Postmenopausal Vaginal Atrophy (PVA) Therapeutics Segment by Type

Drugs Treatment

Other Treatments

Postmenopausal Vaginal Atrophy (PVA) Therapeutics Segment by Application

Hospital

Clinic

Others

Postmenopausal Vaginal Atrophy (PVA) Therapeutics Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Postmenopausal Vaginal Atrophy (PVA) Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Postmenopausal Vaginal Atrophy (PVA) Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Postmenopausal Vaginal Atrophy (PVA) Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 5: Detailed analysis of Postmenopausal Vaginal Atrophy (PVA) Therapeutics companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.

Chapter 12: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size (US$ Million) Comparison by Region: 2021 VS 2025 VS 2032 Table 2. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Region (2021-2026) & (US$ Million) Table 3. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Share by Region (2021-2026) Table 4. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Region (2027-2032) & (US$ Million) Table 5. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Share by Region (2027-2032) Table 6. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Type (2021-2026) & (US$ Million) Table 8. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Share by Type (2021-2026) Table 9. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Forecasted by Type (2027-2032) & (US$ Million) Table 10. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Share Forecasted by Type (2027-2032) Table 11. North America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 12. North America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 13. Europe Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 14. Europe Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 15. Asia-Pacific Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 16. Asia-Pacific Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 17. Latin America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 18. Latin America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 19. Middle East and Africa Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 20. Middle East and Africa Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 21. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 22. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Application (2021-2026) & (US$ Million) Table 23. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Share by Application (2021-2026) Table 24. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Forecasted by Application (2027-2032) & (US$ Million) Table 25. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Share Forecasted by Application (2027-2032) Table 26. North America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 27. North America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 28. Europe Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 29. Europe Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 30. Asia-Pacific Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 31. Asia-Pacific Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 32. Latin America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 33. Latin America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 34. Middle East and Africa Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 35. Middle East and Africa Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 36. Postmenopausal Vaginal Atrophy (PVA) Therapeutics Industry Trends Table 37. Postmenopausal Vaginal Atrophy (PVA) Therapeutics Industry Drivers Table 38. Postmenopausal Vaginal Atrophy (PVA) Therapeutics Industry Opportunities and Challenges Table 39. Postmenopausal Vaginal Atrophy (PVA) Therapeutics Industry Restraints Table 40. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Company (US$ Million) & (2021-2026) Table 41. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue Market Share by Company (2021-2026) Table 42. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Industry Company Ranking, 2024 VS 2025 VS 2026 Table 43. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Key Company Headquarters & Area Served Table 44. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Company, Product Type & Application Table 45. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Company Commercialization Time Table 46. Global Company Market Concentration Ratio (CR5 and HHI) Table 47. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 48. Teva Pharmaceuticals Company Information Table 49. Teva Pharmaceuticals Business Overview Table 50. Teva Pharmaceuticals Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 51. Teva Pharmaceuticals Postmenopausal Vaginal Atrophy (PVA) Therapeutics Product Portfolio Table 52. Teva Pharmaceuticals Recent Development Table 53. Pfizer Company Information Table 54. Pfizer Business Overview Table 55. Pfizer Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 56. Pfizer Postmenopausal Vaginal Atrophy (PVA) Therapeutics Product Portfolio Table 57. Pfizer Recent Development Table 58. Shionogi & Co Company Information Table 59. Shionogi & Co Business Overview Table 60. Shionogi & Co Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 61. Shionogi & Co Postmenopausal Vaginal Atrophy (PVA) Therapeutics Product Portfolio Table 62. Shionogi & Co Recent Development Table 63. Novo Nordisk Company Information Table 64. Novo Nordisk Business Overview Table 65. Novo Nordisk Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 66. Novo Nordisk Postmenopausal Vaginal Atrophy (PVA) Therapeutics Product Portfolio Table 67. Novo Nordisk Recent Development Table 68. Endoceutics Company Information Table 69. Endoceutics Business Overview Table 70. Endoceutics Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 71. Endoceutics Postmenopausal Vaginal Atrophy (PVA) Therapeutics Product Portfolio Table 72. Endoceutics Recent Development Table 73. Accord Healthcare Company Information Table 74. Accord Healthcare Business Overview Table 75. Accord Healthcare Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 76. Accord Healthcare Postmenopausal Vaginal Atrophy (PVA) Therapeutics Product Portfolio Table 77. Accord Healthcare Recent Development Table 78. North America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 79. North America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Country (2021-2026) & (US$ Million) Table 80. North America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Share by Country (2021-2026) Table 81. North America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Forecast by Country (2027-2032) & (US$ Million) Table 82. North America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Share Forecast by Country (2027-2032) Table 83. Europe Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 84. Europe Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Country (2021-2026) & (US$ Million) Table 85. Europe Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Share by Country (2021-2026) Table 86. Europe Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Forecast by Country (2027-2032) & (US$ Million) Table 87. Europe Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Share Forecast by Country (2027-2032) Table 88. Asia-Pacific Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 89. Asia-Pacific Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Country (2021-2026) & (US$ Million) Table 90. Asia-Pacific Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Share by Country (2021-2026) Table 91. Asia-Pacific Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Forecast by Country (2027-2032) & (US$ Million) Table 92. Asia-Pacific Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Share Forecast by Country (2027-2032) Table 93. Latin America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 94. Latin America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Country (2021-2026) & (US$ Million) Table 95. Latin America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Share by Country (2021-2026) Table 96. Latin America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Forecast by Country (2027-2032) & (US$ Million) Table 97. Latin America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Share Forecast by Country (2027-2032) Table 98. Middle East & Africa Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 99. Middle East & Africa Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Country (2021-2026) & (US$ Million) Table 100. Middle East & Africa Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Share by Country (2021-2026) Table 101. Middle East & Africa Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Forecast by Country (2027-2032) & (US$ Million) Table 102. Middle East & Africa Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Share Forecast by Country (2027-2032) Table 103. Research Programs/Design for This Report Table 104. Authors List of This Report Table 105. Secondary Sources List of Figures Figure 1.List of Figures Figure 2. Postmenopausal Vaginal Atrophy (PVA) Therapeutics Product Image Figure 3. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 4. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 5. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Share by Region: 2025 VS 2032 Figure 6. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Share by Region (2021-2032) Figure 7. North America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Growth Rate (2021-2032) & (US$ Million) Figure 8. Europe Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Growth Rate (2021-2032) & (US$ Million) Figure 9. Asia-Pacific Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Growth Rate (2021-2032) & (US$ Million) Figure 10. Latin America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Growth Rate (2021-2032) & (US$ Million) Figure 11. Middle East & Africa Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Growth Rate (2021-2032) & (US$ Million) Figure 12. Drugs Treatment Image Figure 13. Global Drugs Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 14. Other Treatments Image Figure 15. Global Other Treatments Market Size YoY Growth (2021-2032) & (US$ Million) Figure 16. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Overview by Type (2021-2032) & (US$ Million) Figure 17. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Share by Type 2025 VS 2032 Figure 18. North America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Share by Type (2021-2032) Figure 19. Europe Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Share by Type (2021-2032) Figure 20. Asia-Pacific Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Share by Type (2021-2032) Figure 21. Latin America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Share by Type (2021-2032) Figure 22. Middle East and Africa Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Share by Type (2021-2032) Figure 23. Hospital Image Figure 24. Global Hospital Market Size YoY Growth (2021-2032) & (US$ Million) Figure 25. Clinic Image Figure 26. Global Clinic Market Size YoY Growth (2021-2032) & (US$ Million) Figure 27. Others Image Figure 28. Global Others Market Size YoY Growth (2021-2032) & (US$ Million) Figure 29. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Overview by Application (2021-2032) & (US$ Million) Figure 30. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Share by Application 2025 VS 2032 Figure 31. North America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Share by Application (2021-2032) Figure 32. Europe Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Share by Application (2021-2032) Figure 33. Asia-Pacific Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Share by Application (2021-2032) Figure 34. Latin America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Share by Application (2021-2032) Figure 35. Middle East and Africa Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Share by Application (2021-2032) Figure 36. Global Top 5 and 10 Postmenopausal Vaginal Atrophy (PVA) Therapeutics Players Market Share by Revenue in 2025 Figure 37. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 38. North America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 39. North America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Share by Country: 2021 VS 2025 VS 2032 Figure 40. North America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Share by Country (2021-2032) Figure 41. Europe Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 42. Europe Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Share by Country: 2021 VS 2025 VS 2032 Figure 43. Europe Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Share by Country (2021-2032) Figure 44. Asia-Pacific Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 45. Asia-Pacific Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Share by Country: 2021 VS 2025 VS 2032 Figure 46. Asia-Pacific Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Share by Country (2021-2032) Figure 47. Latin America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. Latin America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Latin America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Share by Country (2021-2032) Figure 50. Middle East & Africa Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 51. Middle East & Africa Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Share by Country: 2021 VS 2025 VS 2032 Figure 52. Middle East & Africa Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Share by Country (2021-2032) Figure 53. Years Considered Figure 54. Research Process Figure 55. Key Executives Interviewed

Scope & coverage.

Types
  • Drugs Treatment
  • Other Treatments
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Teva Pharmaceuticals
  • Pfizer
  • Shionogi & Co
  • Novo Nordisk
  • Endoceutics
  • Accord Healthcare

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.3 Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Overview by Region 2021 VS 2025 VS 2032
  4. 1.4 Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Region (2021-2032)
  5. 1.4.1 Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Region (2021-2026)
  6. 1.4.2 Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Region (2027-2032)
  7. 1.5 Key Regions Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size (2021-2032)
  8. 1.5.1 North America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Growth Rate (2021-2032)
  9. 1.5.2 Europe Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Growth Rate (2021-2032)
  10. 1.5.3 Asia-Pacific Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Growth Rate (2021-2032)
  11. 1.5.4 South America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Growth Rate (2021-2032)
  12. 1.5.5 Middle East & Africa Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Growth Rate (2021-2032)
2 Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market by Type
  1. 2.1 Type Introduction
  2. 2.1.1 Drugs Treatment
  3. 2.1.2 Other Treatments
  4. 2.2 Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Type
  5. 2.2.1 Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Overview by Type (2021-2032)
  6. 2.2.2 Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Historic Market Size Review by Type (2021-2026)
  7. 2.2.3 Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Forecasted by Type (2027-2032)
  8. 2.3 Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Regions
  9. 2.3.1 North America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Breakdown by Type (2021-2026)
  10. 2.3.2 Europe Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Breakdown by Type (2021-2026)
  11. 2.3.3 Asia-Pacific Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Breakdown by Type (2021-2026)
  12. 2.3.4 South America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Breakdown by Type (2021-2026)
  13. 2.3.5 Middle East and Africa Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Breakdown by Type (2021-2026)
3 Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market by Application
  1. 3.1 Type Introduction
  2. 3.1.1 Hospital
  3. 3.1.2 Clinic
  4. 3.1.3 Others
  5. 3.2 Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Application
  6. 3.2.1 Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Overview by Application (2021-2032)
  7. 3.2.2 Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Historic Market Size Review by Application (2021-2026)
  8. 3.2.3 Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Forecasted by Application (2027-2032)
  9. 3.3 Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Regions
  10. 3.3.1 North America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Breakdown by Application (2021-2026)
  11. 3.3.2 Europe Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Breakdown by Application (2021-2026)
  12. 3.3.3 Asia-Pacific Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Breakdown by Application (2021-2026)
  13. 3.3.4 South America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Breakdown by Application (2021-2026)
  14. 3.3.5 Middle East and Africa Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
  1. 4.1 Postmenopausal Vaginal Atrophy (PVA) Therapeutics Industry Trends
  2. 4.2 Postmenopausal Vaginal Atrophy (PVA) Therapeutics Industry Drivers
  3. 4.3 Postmenopausal Vaginal Atrophy (PVA) Therapeutics Industry Opportunities and Challenges
  4. 4.4 Postmenopausal Vaginal Atrophy (PVA) Therapeutics Industry Restraints
5 Competitive Insights by Company
  1. 5.1 Global Top Players by Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue (2021-2026)
  2. 5.2 Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Industry Company Ranking, 2024 VS 2025 VS 2026
  3. 5.3 Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Key Company Headquarters & Area Served
  4. 5.4 Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Company, Product Type & Application
  5. 5.5 Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Company Commercialization Time
  6. 5.6 Market Competitive Analysis
  7. 5.6.1 Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market CR5 and HHI
  8. 5.6.2 Global Top 5 and 10 Postmenopausal Vaginal Atrophy (PVA) Therapeutics Players Market Share by Revenue in 2025
  9. 5.6.3 2025 Postmenopausal Vaginal Atrophy (PVA) Therapeutics Tier 1, Tier 2, and Tier 3
6 Company Profiles
  1. 6.1 Teva Pharmaceuticals
  2. 6.1.1 Teva Pharmaceuticals Company Information
  3. 6.1.2 Teva Pharmaceuticals Business Overview
  4. 6.1.3 Teva Pharmaceuticals Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
  5. 6.1.4 Teva Pharmaceuticals Postmenopausal Vaginal Atrophy (PVA) Therapeutics Product Portfolio
  6. 6.1.5 Teva Pharmaceuticals Recent Developments
  7. 6.2 Pfizer
  8. 6.2.1 Pfizer Company Information
  9. 6.2.2 Pfizer Business Overview
  10. 6.2.3 Pfizer Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
  11. 6.2.4 Pfizer Postmenopausal Vaginal Atrophy (PVA) Therapeutics Product Portfolio
  12. 6.2.5 Pfizer Recent Developments
  13. 6.3 Shionogi & Co
  14. 6.3.1 Shionogi & Co Company Information
  15. 6.3.2 Shionogi & Co Business Overview
  16. 6.3.3 Shionogi & Co Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
  17. 6.3.4 Shionogi & Co Postmenopausal Vaginal Atrophy (PVA) Therapeutics Product Portfolio
  18. 6.3.5 Shionogi & Co Recent Developments
  19. 6.4 Novo Nordisk
  20. 6.4.1 Novo Nordisk Company Information
  21. 6.4.2 Novo Nordisk Business Overview
  22. 6.4.3 Novo Nordisk Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
  23. 6.4.4 Novo Nordisk Postmenopausal Vaginal Atrophy (PVA) Therapeutics Product Portfolio
  24. 6.4.5 Novo Nordisk Recent Developments
  25. 6.5 Endoceutics
  26. 6.5.1 Endoceutics Company Information
  27. 6.5.2 Endoceutics Business Overview
  28. 6.5.3 Endoceutics Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
  29. 6.5.4 Endoceutics Postmenopausal Vaginal Atrophy (PVA) Therapeutics Product Portfolio
  30. 6.5.5 Endoceutics Recent Developments
  31. 6.6 Accord Healthcare
  32. 6.6.1 Accord Healthcare Company Information
  33. 6.6.2 Accord Healthcare Business Overview
  34. 6.6.3 Accord Healthcare Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
  35. 6.6.4 Accord Healthcare Postmenopausal Vaginal Atrophy (PVA) Therapeutics Product Portfolio
  36. 6.6.5 Accord Healthcare Recent Developments
7 North America
  1. 7.1 North America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 7.2 North America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Country (2021-2026)
  3. 7.3 North America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Forecast by Country (2027-2032)
8 Europe
  1. 8.1 Europe Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 8.2 Europe Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Country (2021-2026)
  3. 8.3 Europe Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
  1. 9.1 Asia-Pacific Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 9.2 Asia-Pacific Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Country (2021-2026)
  3. 9.3 Asia-Pacific Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Forecast by Country (2027-2032)
10 South America
  1. 10.1 South America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 10.2 South America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Country (2021-2026)
  3. 10.3 South America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
  1. 11.1 Middle East & Africa Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 11.2 Middle East & Africa Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Country (2021-2026)
  3. 11.3 Middle East & Africa Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Forecast by Country (2027-2032)
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst